A Three-arm, Parallel Group, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in a 13- to 17-year-old Autism Spectrum Disorder Population [1]
The primary objective of this study is to evaluate the effectiveness and safety of an investigational medication compared with placebo in improving irritability symptoms in individuals with ASD.
Study Length:
Approximately 4 months
Disorder/Condition:
Autism
Inclusion Criteria:
Males and Females, ages 13-17 with ASD and presence of irritability and GI symptoms
Study Title (brief):
A Three-arm, Parallel Group, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in a 13- to 17-year-old Autism Spectrum Disorder Population
Study Description (brief):
The primary objective of this study is to evaluate the effectiveness and safety of an investigational medication compared with placebo in improving irritability symptoms in individuals with ASD.
Study Contact:
Clinical Evaluation Center at 845-398-2184 or vrp@nki.rfmh.org [2]
Study Location:
Nathan Kline Institute, Orangeburg, NY